R R

What Is Rivaroxaban?

Rivaroxaban is a prescription anticoagulant belonging to the direct factor Xa inhibitor class. It is used to treat or prevent certain blood clots and reduce the risk of selected cardiovascular complications. Rivaroxaban is the active ingredient in Xarelto and is available as oral tablets and an oral suspension for eligible patients. Its approved uses include prevention of stroke in patients with nonvalvular atrial fibrillation, treatment of deep vein thrombosis and pulmonary embolism, and prevention of certain clotting events. It does not dissolve existing clots directly. Rivaroxaban carries boxed warnings concerning premature treatment discontinuation and spinal or epidural bleeding.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Rivaroxaban?

Rivaroxaban is a prescription anticoagulant belonging to the direct factor Xa inhibitor class. It is used to treat or prevent certain blood clots and reduce the risk of selected cardiovascular complications. Rivaroxaban is the active ingredient in Xarelto and is available as oral tablets and an oral suspension for eligible patients. Its approved uses include prevention of stroke in patients with nonvalvular atrial fibrillation, treatment of deep vein thrombosis and pulmonary embolism, and prevention of certain clotting events. It does not dissolve existing clots directly. Rivaroxaban carries boxed warnings concerning premature treatment discontinuation and spinal or epidural bleeding.

read more about rivaroxaban ...

Copy this HTML:

Copy HTML Copied!

How Does Rivaroxaban Work?

Rivaroxaban selectively inhibits activated clotting factor X, also called factor Xa. This protein participates in the coagulation cascade by helping convert prothrombin into thrombin. Thrombin is necessary for converting fibrinogen into fibrin, which forms the structural framework of blood clots. By blocking factor Xa, rivaroxaban reduces thrombin generation and the formation of new clots. It also helps prevent existing clots from growing while the body's natural processes gradually break them down. Rivaroxaban does not directly dissolve clots and does not require routine INR monitoring like warfarin. Its anticoagulant activity increases the risk of bleeding.

What Conditions Does Rivaroxaban Treat or Prevent?

Rivaroxaban is approved to reduce stroke and systemic embolism risk in adults with nonvalvular atrial fibrillation. It also treats deep vein thrombosis and pulmonary embolism, reduces recurrent clot risk, and prevents certain blood clots following hip or knee replacement surgery or during and after hospitalization for selected acute illnesses. Low-dose rivaroxaban combined with aspirin reduces certain cardiovascular events in eligible adults with coronary or peripheral artery disease. Pediatric indications include treatment and prevention of recurrent venous thromboembolism after initial anticoagulation and clot prevention following the Fontan procedure in eligible children. Patient selection depends on kidney function, bleeding risk, and the specific indication.

How Should Rivaroxaban Be Taken?

Rivaroxaban is taken orally according to the condition being treated. Adults with nonvalvular atrial fibrillation commonly take 20 mg once daily with the evening meal, or 15 mg with the evening meal when kidney function meets the labeled dose-reduction criteria. For acute deep vein thrombosis or pulmonary embolism, treatment generally begins at 15 mg twice daily with food for 21 days, followed by 20 mg once daily with food. Extended prevention may use 10 mg daily after at least six months of standard treatment. For coronary or peripheral artery disease, 2.5 mg twice daily is combined with low-dose aspirin. Pediatric doses are weight-based. Patients should not stop treatment without medical direction.

What Are the Side Effects and Warnings of Rivaroxaban?

Bleeding is the principal adverse effect of rivaroxaban and may include easy bruising, nosebleeds, gastrointestinal bleeding, or serious internal hemorrhage. Rivaroxaban carries boxed warnings for increased thrombotic risk after premature discontinuation and spinal or epidural hematomas associated with certain procedures. Serious bleeding can be life-threatening. Patients with active pathological bleeding must not use rivaroxaban. Kidney impairment, liver disease, and interactions with certain medications can increase treatment risks. Patients should report black stools, blood in the urine, prolonged bleeding, or unusual bruising. Severe headache, sudden weakness, coughing blood, or uncontrolled bleeding requires emergency care.

Common Questions About Rivaroxaban

Is rivaroxaban the same as Xarelto?

Yes. Xarelto is a brand name for rivaroxaban, a direct factor Xa inhibitor used to treat and prevent selected blood clots.

Does rivaroxaban dissolve blood clots?

No. Rivaroxaban reduces clot formation and prevents existing clots from growing while the body gradually breaks them down.

Does rivaroxaban need to be taken with food?

The 15 mg and 20 mg adult tablets must be taken with food. The 2.5 mg and 10 mg tablets may be taken with or without food, depending on the prescribed regimen.

Can rivaroxaban be stopped suddenly?

Stopping rivaroxaban prematurely can increase the risk of serious blood clots. Patients should consult their prescriber before interrupting treatment.

References

DailyMed - XARELTO (rivaroxaban) tablets and granules for oral suspension. https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610. Date Accessed November 4, 2026.

Rivaroxaban. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK548015/. Date Accessed November 4, 2026.

Rivaroxaban. MedlinePlus. https://medlineplus.gov/druginfo/meds/a611049.html. Date Accessed November 4, 2026.

Rivaroxaban. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Rivaroxaban. Date Accessed November 4, 2026.

Rivaroxaban. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK557502/. Date Accessed November 4, 2026.